Whether a company conducts joint research with a global pharmaceutical company has emerged as a key variable determining the stock prices of domestic biotech shares. Until recently, expectations for technology transfers and co-development in the obesity and diabetes treatment market had driven volatility in related stocks. However, this time, a case has emerged where the opposite dynamic—differences in interpreting the scope of joint research—served as the trigger for a sharp decline.

The direct cause of the plunge was certain media reports covering remarks by Peptron CEO Choi Ho-il regarding the scope of joint research. It is analyzed that the market interpreted these as a signal of either a reduction in the value of the joint research or its termination, leading to a rapid contraction in investor sentiment.

Peptron immediately stepped in to contain the damage through an official statement on the day it hit the lower limit. The company stated that the ongoing joint research is not limited to the single product mentioned at the forum in question. It explained that research on multiple compounds, spanning next-generation obesity and diabetes drug candidates held by the global pharmaceutical company as well as the central nervous system (CNS) sector, is proceeding as planned.

Additionally, the company drew a clear line regarding reports about a contract between another company and the global pharmaceutical company, stating that this reflected the CEO's personal opinion and not the company's official position.

[※ This article is intended for informational purposes, and investment decisions and their associated responsibilities lie solely with the investor. As matters related to specific stocks and companies are highly volatile and fluid, please verify further through the latest disclosures and multiple sources before making any investment decisions. This is an article partially assisted by AI.]